Results of AMAS® DETERMINATION

(Anti-Malignin Antibody in Serum, determined with Target® Reagent)

Oncolab

36 Fenway, Boston, MA. 02215

p (617) 536-0850 f (617) 536-0657

www.oncolabinc.com

111363

Physician's Name: Blanke, Janice

Fax Number (819) 687-9926

Patient's Name Bastian, John

Determination Date 9/21/2011

Lab Director: Samuel Bogoch, M.D., Ph.D

Technician: Walsh, Kevin

Component Results

AMA ug/m	S-TAG	F-TAG	Net TAG
700-			
500-699			
400-499			
300-399			
135-299	211		
100-134		130	
25-99			81
0-24			

Overall Result

[ ] **ELEVATED**
Confirmatory repeat test recommended

[ ] **BORDERLINE**
Confirmatory repeat test recommended

[X] **NORMAL**
Can also occur in successfully treated cancer patients with "no evidence of disease" and in advanced or terminal patients with antibody faliure

[ ] **INCONCLUSIVE**
Duplicates do not agree, or laboratory error; please repeat at Oncolab's expense

Notes: LIMITATIONS AND WARNINGS

(See References below) If repeat determinations agree, the false-positive and false negative rates are less than 1% (specificity and sensitivity greater than 99%); in single determinations, false positives are 5% and false negatives 7% (3,315 double-blind tests of patients and controls, ref.4,6, and 8); AMAS antibody, determined in this test, tends to be detected earlier than antigens, and is of potental help in early detection. However, since antibody fails terminally the test cannot be used as a diagnostic aid late in the disease. The level of AMAS is quantitatively related to survival in known cancer patients; the higher the level of AMAS the longer the predicted survival. As in all clinical laboratory tests, the AMAS Test is not by itself diagnostic of the presence or absence of disease, and its results can only be assessed as an aid to diagnosis, detection or monitoring of disease in relation to the history, medical signs and symptoms and the overall condition of the patient.



References

1. National Cancer Institute Mon. 46:133-137,1977
2. Lancet 1 :987, 1979
3. Lancet 2: 1411-142, 1981
4.J. Medicine 13:49-69
5.Protides Biol. Fluids 30:337-352, 1983
6.Protides of Biol Fluids 31:739-747,1984
7. Cancer Detection and Prevention 8 No. 5/6 551,1985
8. Cancer Detection and Prevention 11: No.1/2,1987
9. Cancer Detection and Prevention 12 313-320,1988
10. Proc. Annu Meet. Am Assoc. Cancer Res 31: A1550,1990
11. Lancet 337:977,1991
12 Cancer Detection and Prevention 17(1)229,1993
13 Cancer Detection and Prevention 17(1)229,1993
14 Cancer Detection and Prevention 18(1)65-78,1994
15.J. Cell Biochem(NCI)19s:172-185,1994
16.Advances Anti-Aging Med (N.Y. Liebert)pp. 109-125, 1995
17. New York Academy of Science 757:413-417, 1995
18. American Association for Cancer Research 37:486,1996
19 Cancer Detection and Prevention 20(5) 508-509, 1996
20. J. Adv. Med. 10 149-150, 1997
21 Cancer Detection and Prevention 22(1): S-159, 1998
22 Cancer Detection and Prevention 22(1): S-227, 1998
23.Cancer Letters 148:39-48, 2000
24 Cancer Detection and Prevention 24(1): S-156, 2000
25 Cancer Detection and Prevention 24(1): S-162, 2000